Cargando…
Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial
BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with sph...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665032/ https://www.ncbi.nlm.nih.gov/pubmed/36380280 http://dx.doi.org/10.1186/s12886-022-02635-0 |
_version_ | 1784831208983625728 |
---|---|
author | Yu, Shiao Du, Liping Ji, Na Li, Binbin Pang, Xuena li, Xiuhong Ma, Nana Huang, Congcong Fu, Aicun |
author_facet | Yu, Shiao Du, Liping Ji, Na Li, Binbin Pang, Xuena li, Xiuhong Ma, Nana Huang, Congcong Fu, Aicun |
author_sort | Yu, Shiao |
collection | PubMed |
description | BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with spherical equivalent refraction from − 1.00 to -4.00 D who had been wearing OK lenses successfully for 2 months (as baseline) were randomly assigned in a 1:1 ratio to combination group (combination of OK lens and 0.01% atropine eye drops) and control group (combination of OK lens and placebo). The primary outcome was change in axial length, along with secondary outcomes including change in pupil diameter (PD) and accommodative amplitude (AMP) at 12 months (measured at 4-month intervals). RESULTS: After 12 months, the overall axial elongation was 0.10 ± 0.14 mm and 0.20 ± 0.15 mm (p = 0.01) in the combination and control groups, respectively. The change in axial length in the two groups showed significant differences only in the first four months (median [Q1, Q3] (95% CI), -0.01 mm [-0.07, 0.05] (-0.06, 0.04) vs. 0.04 mm [0.00, 0.10] (0.02, 0.09); p = 0.04), but no difference thereafter. Multivariate linear regression analysis showed that the axial elongation was significantly slower in the combination group than in the control group (standard β = -0.10, p = 0.02). PD significantly increased by 0.45 mm [0.20, 0.68] at the 4th month visit (p < 0.001) and then remained stable in the combination group. The PD in the control group and AMP in the two groups remained stable from baseline to 12 months (all p > 0.05). CONCLUSION: The combination therapy was more effective than the OK lens alone in slowing axial elongation after 12 months of treatment, and mainly in the first 4 months. TRIAL REGISTRATION: The First Affiliated Hospital of Zhengzhou University, ChiCTR2000033904. Registered 16/06/2020, http://www.chictr.org.cn/login.aspx?referurl=%2flistbycreater.aspx |
format | Online Article Text |
id | pubmed-9665032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96650322022-11-16 Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial Yu, Shiao Du, Liping Ji, Na Li, Binbin Pang, Xuena li, Xiuhong Ma, Nana Huang, Congcong Fu, Aicun BMC Ophthalmol Research BACKGROUND: To evaluate the additive effects of orthokeratology (OK) lenses and 0.01% atropine on slowing axial elongation in myopic children. METHODS: A prospective, randomized, double-blinded, placebo-controlled trial was conducted over a 12-month period. Sixty children aged 8 to 12 years with spherical equivalent refraction from − 1.00 to -4.00 D who had been wearing OK lenses successfully for 2 months (as baseline) were randomly assigned in a 1:1 ratio to combination group (combination of OK lens and 0.01% atropine eye drops) and control group (combination of OK lens and placebo). The primary outcome was change in axial length, along with secondary outcomes including change in pupil diameter (PD) and accommodative amplitude (AMP) at 12 months (measured at 4-month intervals). RESULTS: After 12 months, the overall axial elongation was 0.10 ± 0.14 mm and 0.20 ± 0.15 mm (p = 0.01) in the combination and control groups, respectively. The change in axial length in the two groups showed significant differences only in the first four months (median [Q1, Q3] (95% CI), -0.01 mm [-0.07, 0.05] (-0.06, 0.04) vs. 0.04 mm [0.00, 0.10] (0.02, 0.09); p = 0.04), but no difference thereafter. Multivariate linear regression analysis showed that the axial elongation was significantly slower in the combination group than in the control group (standard β = -0.10, p = 0.02). PD significantly increased by 0.45 mm [0.20, 0.68] at the 4th month visit (p < 0.001) and then remained stable in the combination group. The PD in the control group and AMP in the two groups remained stable from baseline to 12 months (all p > 0.05). CONCLUSION: The combination therapy was more effective than the OK lens alone in slowing axial elongation after 12 months of treatment, and mainly in the first 4 months. TRIAL REGISTRATION: The First Affiliated Hospital of Zhengzhou University, ChiCTR2000033904. Registered 16/06/2020, http://www.chictr.org.cn/login.aspx?referurl=%2flistbycreater.aspx BioMed Central 2022-11-15 /pmc/articles/PMC9665032/ /pubmed/36380280 http://dx.doi.org/10.1186/s12886-022-02635-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yu, Shiao Du, Liping Ji, Na Li, Binbin Pang, Xuena li, Xiuhong Ma, Nana Huang, Congcong Fu, Aicun Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title | Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title_full | Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title_fullStr | Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title_full_unstemmed | Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title_short | Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
title_sort | combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665032/ https://www.ncbi.nlm.nih.gov/pubmed/36380280 http://dx.doi.org/10.1186/s12886-022-02635-0 |
work_keys_str_mv | AT yushiao combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT duliping combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT jina combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT libinbin combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT pangxuena combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT lixiuhong combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT manana combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT huangcongcong combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial AT fuaicun combinationoforthokeratologylenswith001atropineinslowingaxialelongationinchildrenwithmyopiaarandomizeddoubleblindedclinicaltrial |